Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Intravenous immunoglobulin treatment for secondary recurrent miscarriage: a randomised, double-blind, placebo-controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Obstetric care for women that use antidepressants in pregnancy

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. Antidepressant use in pregnancy and severe cardiac malformations: Danish register-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cancer in pregnancy increases the risk of venous thromboembolism: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Long-term consequences of prenatal progesterone exposure

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  1. Presence of SARS-CoV-2 in semen and the impact of COVID-19 on the male reproductive system

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Oocytdonation

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

OBJECTIVE: To determine whether infusions with intravenous immunoglobulin (IVIg) during early pregnancy increase live birth rate in women with secondary recurrent miscarriage compared with placebo.

DESIGN: A single-centre, randomised, double-blind, placebo-controlled trial.

SETTING: A tertiary centre for recurrent miscarriage in Copenhagen, Denmark.

POPULATION: A group of 82 women with unexplained secondary recurrent miscarriage and at least four miscarriages.

METHODS: Women were randomly assigned to repeated infusions with IVIg or placebo (albumin) from the time of positive pregnancy test to gestational week 15 or pregnancy loss.

MAIN OUTCOME MEASURE: Primary outcome was birth with neonatal survival in all randomised women.

RESULTS: In the intention-to-treat analyses, live birth rates were 23/42 (54.8%) in the IVIg and 20/40 (50.0%) in the placebo group, relative risk 1.11 (95% CI 0.70-1.74). In a per protocol analysis, almost identical results were found. The median gestational length at delivery was higher in the IVIg than the placebo group (282 versus 272 days, P = 0.02) but the mean birthweight was not significantly increased.

CONCLUSIONS: In this trial, which is the largest so far, IVIg did not increase the live birth rate in patients with secondary recurrent miscarriage and the treatment cannot be recommended in clinical practice.

OriginalsprogEngelsk
TidsskriftBr J Obstet Gynaecol
Vol/bind122
Sider (fra-til)500-508
ISSN1470-0328
DOI
StatusUdgivet - 2015

ID: 44731308